Dr. Thaddeus Beeker, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Brody School of Medicine at East Carolina University (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 312
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Brody School of Medicine at East Carolina University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 00018890
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mobile Infirmary Medical Center Mobile, AL
- North Baldwin Infirmary Bay Minette, AL
Medical groups
- Imc-Diagnostic and Medical Clinic LLC (164 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 312
- Services billed
- 1,091
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 307 | 174 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 222 | 94 |
| Established patient office or other outpatient visit, 40-54 minutes | 187 | 67 |
| Insertion of needle into vein for collection of blood sample | 101 | 64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 96 | 66 |
| Blood test, comprehensive group of blood chemicals | 65 | 48 |
| New patient office or other outpatient visit, 45-59 minutes | 60 | 60 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 52 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 41 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Mobile, AL | 356 |
| Revlimid (lenalidomide) | 103 |
| Letrozole Other prescribers in Mobile, AL | 67 |
| Ondansetron Odt (ondansetron) Other prescribers in Mobile, AL | 60 |
| Prochlorperazine Maleate Other prescribers in Mobile, AL | 55 |
| Hydroxyurea Other prescribers in Mobile, AL | 54 |
| Calquence (acalabrutinib maleate) | 51 |
| Tamoxifen Citrate Other prescribers in Mobile, AL | 48 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Mobile, AL | 46 |
| Eliquis (apixaban) Other prescribers in Mobile, AL | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 60 payments worth $1,370 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $180 |
|---|---|
| Janssen Biotech, Inc. | $176 |
| Merck Sharp & Dohme LLC | $165 |
| Regeneron Healthcare Solutions, Inc. | $99.93 |
| Genzyme Corporation | $97.56 |
| AstraZeneca Pharmaceuticals LP | $95.41 |
| Incyte Corporation | $84.17 |
| Pfizer Inc. | $73.19 |
| Food and Beverage | $1,270 |
|---|---|
| Education | $99.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 30, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $100,080 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.